Literature DB >> 25549803

Prognostic value of inhibitor of apoptosis protein family expression in patients with acute myeloid leukemia.

Agnieszka Pluta1, Agnieszka Wierzbowska1, Barbara Cebula-Obrzut2, Piotr Pluta3, Konrad Stępka1, Anna Szmigielska-Kapłon1, Olga Grzybowska-Izydorczyk2, Magdalena Czemerska1, Piotr Smolewski2, Agata Wrzesien-Kus1, Tadeusz Robak1.   

Abstract

The inhibitor of apoptosis protein (IAP) family acts as an inhibitor of apoptosis pathways. The potential prognostic value of the expression of selected IAP family members, XIAP, cIAP-1, cIAP-2 and survivin protein, was evaluated with regard to treatment response and survival of 56 newly diagnosed adult patients with acute myeloid leukemia (AML). The presence of these IAP members influenced the achievement of a complete response (CR). In addition, overall survival (OS) was influenced by low survivin expression in univariate and multivariate analysis (p = 0.014 and p = 0.013, respectively). A strong correlation was observed between members of the IAP family (XIAP and cIAP-1, XIAP and cIAP-2, cIAP-1 and cIAP-2, p < 0.001 for all comparisons), while Smac/DIABLO demonstrated an inverse correlation with XIAP, cIAP-1 and cIAP-2 (p < 0.001 for all comparisons). Further studies should be undertaken to better demonstrate the mode of action of IAP members, as well as their prognostic and therapeutic potentials.

Entities:  

Keywords:  Acute myeloid leukemia; IAP; apoptosis; prognosis

Mesh:

Substances:

Year:  2015        PMID: 25549803     DOI: 10.3109/10428194.2014.1003052

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.

Authors:  Varun V Prabhu; Mala K Talekar; Amriti R Lulla; C Leah B Kline; Lanlan Zhou; Junior Hall; A Pieter J Van den Heuvel; David T Dicker; Jawad Babar; Stephan A Grupp; Mathew J Garnett; Ultan McDermott; Cyril H Benes; Jeffrey J Pu; David F Claxton; Nadia Khan; Wolfgang Oster; Joshua E Allen; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2018-02-19       Impact factor: 4.534

2.  The role of NF-κB and Smac/DIABLO proteins in the treatment response and survival of acute myeloid leukemia patients.

Authors:  Agnieszka Pluta; Tadeusz Robak; Barbara Cebula; Agata Majchrzak; Piotr Pluta; Kamil Brzozowski; Konrad Stępka; Anna Szmigielska-Kapłon; Olga Grzybowska-Izydorczyk; Magdalena Czemerska; Piotr Smolewski; Agnieszka Wierzbowska
Journal:  Arch Med Sci       Date:  2019-11-19       Impact factor: 3.318

3.  LC3-associated phagocytosis in bone marrow macrophages suppresses acute myeloid leukemia progression through STING activation.

Authors:  Jamie A Moore; Jayna J Mistry; Charlotte Hellmich; Rebecca H Horton; Edyta E Wojtowicz; Aisha Jibril; Matthew Jefferson; Thomas Wileman; Naiara Beraza; Kristian M Bowles; Stuart A Rushworth
Journal:  J Clin Invest       Date:  2022-03-01       Impact factor: 14.808

Review 4.  A Review of the Current Impact of Inhibitors of Apoptosis Proteins and Their Repression in Cancer.

Authors:  Pierina Cetraro; Julio Plaza-Diaz; Alex MacKenzie; Francisco Abadía-Molina
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

5.  Peripheral blood marker of residual acute leukemia after hematopoietic cell transplantation using multi-plex digital droplet PCR.

Authors:  M Stanojevic; M Grant; S K Vesely; S Knoblach; C G Kanakry; J Nazarian; E Panditharatna; K Panchapakesan; R E Gress; J Holter-Chakrabarty; Kirsten M Williams
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

Review 6.  Targeting apoptosis in acute myeloid leukaemia.

Authors:  Philippe A Cassier; Marie Castets; Amine Belhabri; Norbert Vey
Journal:  Br J Cancer       Date:  2017-08-24       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.